Wearable Neuromodulation Device Launched by Teen Siblings

Laird Harrison

January 07, 2022

A portable neuromodulation device can put the user in a meditative state with the potential to ease chronic pain, according to its teenage inventors.

The Fluxwear Shift pulses electromagnetic energy into the user's brain, synchronizing neurons in patterns that resemble meditation, said Kamran Ansari, the company's 16-year-old CEO. The low-level stimulation measures in the microteslas.

The Fluxwear Shift, a new neuromodulation device that can be worn anywhere.

Kamran Ansari and his sister, Nadia Ansari, introduced the product at CES 2022, the annual trade show of the Consumer Technology Association.

Kamran and Nadia Ansari, teen founders of Fluxwear.

Yes, you read that right: 16 years old. Kamran Ansari, a math prodigy who studied calculus in middle school, set to work on the device after his sister, Nadia Ansari, 18, began to experience pain from Guillain-Barré syndrome in July 2017. The pain was so severe that she had to stop her high school studies.

Nadia Ansari had tried medication and various other treatments for pain, eventually turning to neuromodulation ― altering nerve activity via electrical stimulation. The large neuromodulation devices used to treat her sometimes provided relief, but they were awkward and the effects inconsistent, she said.

"What I found to be the most effective was pulsation magnetic field, or PMF," says Kamran Ansari. "I found that a lot of the devices that we would bring home for Nadia to use were a little bit more clunky or so hard to use that they didn't allow her to use it portably. My goal became creating a PMF device that allowed her to be comfortable to go to school and do all the things that she wanted to do while receiving therapy."

He designed a device that could be built into a cadet-style cap, delivering low levels of energy through a high number of emitters to create multidirectional fields, and thus increase "synchronicity or functional connectivity of different brain regions," a condition found in profound meditation, he says. "We found this device replicates that effect in 25 minutes of use."

Nadia Ansari began using the device in October 2020 and by March 2021 was feeling much better. "I was able to go back to a lot of physical activity," she says. "Before, I would have trouble just walking around. I had to go undergo a bunch of diet changes to help with the pain, but I was able to go back to eating everything I could before. And I will go back to school to full time."

Ansari has tested the product on other patients, measuring changes in electroencephalography. The company has also launched clinical trials to see if it can document effects on pain and anxiety, he says. It has not yet published any data.

For now, the device has Class I clearance from the US Food and Drug Administration, which covers devices that "present minimal potential for harm to the user and are often simpler in design." Fluxwear is currently promoting the Shift as a meditation aid, not as a treatment for pain or any other medical condition.

Tales of a teenage CEO inventing a cool new product are always fun, but Ansari is serious about Fluxwear and the effectiveness of the company's first product. As they developed the Shift, the siblings received guidance from a group of experts, including Christine Kraus, PhD, a clinical neuropsychologist and associate clinical professor at the University of California, Irvine (UCI); Ali Elahi, MD, a Newport Beach neurologist with expertise in repetitive transcranial magnetic stimulation; and Shaista Malik, MD, PhD, MPH, a UCI professor of medicine and executive director of the Susan Samueli Integrative Health Institute.

While neuromodulation is not new, the exact mechanism of the process is not yet determined, and there are many modalities that differ by the type of energy and the area of the brain targeted, but some have proven efficacious in clinical trials for pain, said Sarah Prinsloo, PhD, an assistant professor of palliative, rehabilitation and integrative medicine in the Department of Neurosurgery at the University of Texas MD Anderson Cancer Center in Houston.

In a 2013 study at the Technical University of Madrid, Spain, for example, patients with fibromyalgia reported improved pain thresholds, as measured with an algometer, after they were stimulated with 8-Hz pulsed magnetic fields of very low intensity. Patients treated with a placebo procedure had no improvement in their pain thresholds.

"[Neuromodulation] is just something patients can have in their toolbox to help treat their symptoms without adding another medication, especially in populations that are already pretty heavily medicated, such as for pain," Prinsloo said. "I get really nothing but positive feedback from physicians."

Prinsloo acknowledged that there is "potentially a lot of hype as well," and she has no connection to the Ansaris or knowledge of the Shift other than the information from the company website. a device that works with one kind of pain may not work with another. The optimal energy level, type of energy, frequency, pace, and target can vary depending on the etiology of pain, the patient's coping mechanisms, and medications, among other factors. "It's pretty complicated, and that's why it's difficult to nail down the mechanism," she said.

Transcranial magnetic stimulation can cause side effects, including seizures, but those occur mostly with the large, powerful devices used in medical clinics, Prinsloo said. Fluxwear so far reports no side effects with their device.

For now, the company is collecting preorders for the Shift. It also offers weekly demonstrations open to the public at its offices in Irvine, California, says Nadia Ansari, also the company's chief operating officer. "We want people to actually try it and see how it works for them before they buy it," she says.

The Ansaris plan to commercialize the Shift in spring of this year. In the meantime, they will continue their studies at their high school in Newport Beach, California.

The Ansaris are founders of Fluxwear. Prinsloo reported no relevant financial relationships.

Laird Harrison writes about science, health, and culture. His work has appeared in magazines, newspapers, on public radio, and on websites. He is at work on a novel about alternate realities in physics. Harrison teaches writing at the Writers Grotto. Visit him at lairdharrison.com or follow him on Twitter: @LairdH.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.